SGLT2 inhibitor luseogliflozin bests DPP4 inhibitors among diabetes patients

For this purpose, the researchers enrolled 623 patients with T2DM who had not used antidiabetic agents or who had used antidiabetic agents other than DPP4 inhibitors and SGLT2 inhibitors after their written informed consent. The enrolled patients were randomly assigned to either the luseogliflozin or DPP-4i group and followed for 52 weeks. The primary (composite) endpoint was the proportion of patients who showed improvement in ≥ 3 endpoints among the following five endpoints from baseline to week 52: eGFR, HbA1c, pulse rate, and systolic blood pressure.

The study led to the following findings:

• The proportion of patients who showed improvement in ≥ 3 endpoints at week 52 was significantly higher in the luseogliflozin group (58.9%) than in the DPP-4i group (35.0%).
• When stratified by body mass index (< 25 or ≥ 25 kg/m2) or age (< 65 or ≥ 65 years), regardless of BMI or age, the proportion of patients who achieved the composite endpoint was significantly higher in the luseogliflozin group than in the DPP-4i group.
• Hepatic function and high-density lipoprotein-cholesterol were also significantly improved in the luseogliflozin group compared with the DPP-4i group.
• The frequency of non-serious/serious adverse events did not differ between the groups.

"The results suggest the criticality of evaluating multiple aspects regarding the effects of diabetes management," the authors concluded.

Reference:

Sugawara, M., Fukuda, M., Sakuma, I. et al. Overall Efficacy and Safety of Sodium-Glucose Cotransporter 2 Inhibitor Luseogliflozin Versus Dipeptidyl-Peptidase 4 Inhibitors: Multicenter, Open-Label, Randomized-Controlled Trial (J-SELECT study). Diabetes Ther (2023). https://doi.org/10.1007/s13300-023-01438-w